Semanteon Capital Management LP Invests $307,000 in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)

Semanteon Capital Management LP purchased a new stake in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 19,009 shares of the company’s stock, valued at approximately $307,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of DCPH. China Universal Asset Management Co. Ltd. grew its stake in Deciphera Pharmaceuticals by 96.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 2,026 shares of the company’s stock valued at $26,000 after purchasing an additional 997 shares in the last quarter. Exchange Traded Concepts LLC grew its position in shares of Deciphera Pharmaceuticals by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 10,447 shares of the company’s stock worth $169,000 after buying an additional 2,649 shares in the last quarter. Diversified Trust Co acquired a new stake in Deciphera Pharmaceuticals in the fourth quarter valued at $193,000. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Deciphera Pharmaceuticals by 20.9% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,178 shares of the company’s stock valued at $196,000 after acquiring an additional 2,102 shares in the last quarter. Finally, Aigen Investment Management LP bought a new position in Deciphera Pharmaceuticals during the 3rd quarter valued at $181,000. 70.96% of the stock is owned by institutional investors and hedge funds.

Deciphera Pharmaceuticals Price Performance

Shares of NASDAQ DCPH opened at $14.65 on Friday. The business has a 50 day simple moving average of $15.59 and a 200 day simple moving average of $14.30. Deciphera Pharmaceuticals, Inc. has a 52 week low of $9.90 and a 52 week high of $17.73.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last announced its quarterly earnings results on Tuesday, February 6th. The company reported ($0.54) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.04. The company had revenue of $48.30 million during the quarter, compared to analysts’ expectations of $45.93 million. Deciphera Pharmaceuticals had a negative return on equity of 49.44% and a negative net margin of 119.33%. The business’s quarterly revenue was up 32.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.60) earnings per share. Equities analysts expect that Deciphera Pharmaceuticals, Inc. will post -2.16 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on DCPH shares. Stifel Nicolaus boosted their price objective on Deciphera Pharmaceuticals from $22.00 to $23.00 and gave the company a “buy” rating in a research report on Wednesday, February 7th. JPMorgan Chase & Co. boosted their price target on shares of Deciphera Pharmaceuticals from $14.00 to $16.00 and gave the company a “neutral” rating in a report on Wednesday, March 20th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, Deciphera Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $23.00.

Deciphera Pharmaceuticals Profile

Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.